6696Lin BioScience6696 info
$4.14info-1.09%24h
Global rank13787
Market cap$325.20M
Change 7d1.12%
YTD Performance18.34%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Lin BioScience (6696) Stock Overview

    Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.

    6696 Stock Information

    Symbol
    6696
    Address
    No. 68, Zhongxiao East RoadTaipei, 110Taiwan
    Founded
    -
    Trading hours
    -
    Website
    https://www.linbioscience.com
    Country
    🇹🇼 Taiwan
    Phone Number
    886 2 8780 5008

    Lin BioScience (6696) Price Chart

    -
    Value:-

    Lin BioScience Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $4.14
    N/A
    Market Cap
    $325.20M
    N/A
    Shares Outstanding
    78.48M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org